Comparison of the Efficacy of Moxifloxacin Preparations in the Therapy of Conjunctivitis
Abstract
Purpose. To evaluate the efficacy and safety of therapy in patients with bacterial conjunctivitis using Moxioftan® eye drops, 5 mg/mL, 5 mL (JADRAN-GALENSKI LABORATORIJ, Croatia), and Vigamox® eye drops, 5 mg/mL, 5 mL (Alcon Laboratories, Inc., USA). Patients and methods. A multicenter, open-label, randomized, comparative clinical trial included 220 patients who were randomized into the Moxioftan® (moxifloxacin) group (n = 110) as the main group or the Vigamox® (moxifloxacin) group (n = 110) as the control group. The primary efficacy endpoint was the frequency of clinical cure, defined as the disappearance of clinical signs of bacterial conjunctivitis at the final study visit (visit 5, day 9 ± 1). Secondary efficacy endpoints included the degree of bacterial eradication, defined as the absence of growth of the primary pathogen identified in the baseline conjunctival smear by day 9 ± 1, dynamics of clinical symptoms of bacterial conjunctivitis, treatment efficacy assessed by both investigators and patients. The safety evaluation included an assessment of the incidence of adverse events, serious adverse events, and their potential relationship to the investigational and comparator drugs. Statistical analysis was performed using the R statistical package v. 3.2.1 and Statistica 10. Results. The clinical cure rate by day 9 ± 1 of the study (visit 5) was 100 % in both the main and control groups. The severity of clinical symptoms of bacterial conjunctivitis decreased equally in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 220 participants or records.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.